Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ophthalmic biosimilars: Lessons from India.

× No keyword cloud information.

3 in total

1. Biotherapeutics and immunogenicity: ophthalmic perspective.

Authors: Ashish Sharma; Nilesh Kumar; Baruch D Kuppermann; Francesco Bandello; Anat Loewenstein
Journal: Eye (Lond) Date: 2019-04-09 Impact factor: 3.775

2. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.

Authors: Eric H Souied; Pravin U Dugel; Alberto Ferreira; Ron Hashmonay; Jingsong Lu; Simon P Kelly
Journal: Ophthalmic Epidemiol Date: 2016-02-08 Impact factor: 1.648

Review 3. Biosimilars in ophthalmology: "Is there a big change on the horizon?"

Authors: Ashish Sharma; Prahalad Reddy; Baruch D Kuppermann; Francesco Bandello; Anat Lowenstein
Journal: Clin Ophthalmol Date: 2018-10-24

3 in total

5 in total

1. Retina: a unique subspecialty in the biosimilar landscape.

Authors: Ashish Sharma; Nilesh Kumar; Nikulaa Parachuri; Carl D Regillo; Francesco Bandello; Baruch D Kuppermann
Journal: Eye (Lond) Date: 2022-02-21 Impact factor: 4.456

2. Clinical efficacy and safety of Razumab® (CESAR) study: Our experience with the world's first biosimilar Ranibizumab.

Authors: Lalit Verma; Mithun Thulasidas; Ajay Purohit; Avnindra Gupta; Ritesh Narula; Dinesh Talwar
Journal: Indian J Ophthalmol Date: 2021-02 Impact factor: 1.848

3. Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases.

Authors: Debdulal Chakraborty; Michael W Stewart; Jay U Sheth; Tushar K Sinha; Subhendu Boral; Arnab Das; Soumen Mondal; Angshuman Mukherjee
Journal: Ophthalmol Ther Date: 2021-04-17

4. Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey.

Authors: Jay U Sheth; Michael W Stewart; Manoj Khatri; Shashank R Gupta; Shobhit Chawla; Anand Rajendran; Raja Narayanan
Journal: Indian J Ophthalmol Date: 2021-02 Impact factor: 1.848

5. Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study).

Authors: Ashish Sharma; Nilesh Kumar; Nikulaa Parachuri; Francesco Bandello; Baruch D Kuppermann; Anat Loewenstein
Journal: Eye (Lond) Date: 2021-06-22 Impact factor: 4.456

5 in total